Johan Frostegård Selected Research

Rheumatoid Arthritis

1/2021	Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events.
6/2012	Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study.
11/2011	Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study.
10/2011	Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset--a prospective cohort study.
1/2009	Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study.
1/2008	Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study.
9/2007	Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johan Frostegård Research Topics

Disease

35	Atherosclerosis 01/2023 - 01/2001
32	Cardiovascular Diseases (Cardiovascular Disease) 11/2023 - 08/2002
19	Inflammation (Inflammations) 01/2023 - 08/2002
14	Hypertension (High Blood Pressure) 11/2023 - 01/2001
14	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 09/2003
12	Atherosclerotic Plaque (Atheroma) 07/2020 - 01/2005
7	Myocardial Infarction 01/2023 - 12/2003
7	Rheumatoid Arthritis 01/2021 - 09/2007
6	Dyslipidemias (Dyslipidemia) 01/2011 - 08/2002
5	Rupture 11/2017 - 01/2005
4	Type 2 Diabetes Mellitus (MODY) 11/2023 - 11/2015
4	Stroke (Strokes) 01/2022 - 01/2010
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2021 - 12/2003
4	Carotid Artery Diseases 03/2015 - 11/2003
4	Thrombosis (Thrombus) 01/2014 - 09/2004
4	Insulin Resistance 01/2011 - 12/2003
3	Hyperlipidemias (Hyperlipidemia) 11/2023 - 11/2015
3	Obesity 10/2021 - 05/2018
3	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 09/2005
3	Infections 03/2020 - 09/2009
3	Pain (Aches) 07/2018 - 06/2012
2	Neoplasms (Cancer) 10/2021 - 01/2018
2	Ischemic Stroke 12/2016 - 04/2009
2	Nephritis 03/2015 - 09/2003
2	Necrosis 11/2011 - 03/2006
1	Venous Thrombosis (Deep-Vein Thrombosis) 01/2023
1	Antiphospholipid Syndrome (Antiphospholipid Antibody Syndrome) 01/2023
1	Uremia 01/2021
1	Chronic Disease (Chronic Diseases) 12/2020
1	Body Weight (Weight, Body) 12/2020
1	Rheumatic Diseases (Rheumatism) 01/2020
1	Lupus Nephritis 01/2020
1	Mixed Connective Tissue Disease (MCTD) 01/2020
1	Fatigue 07/2018
1	Overweight 05/2018
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2018
1	Genetic Risk Score 01/2018
1	Spondyloenchondrodysplasia 01/2017
1	Coronary Disease (Coronary Heart Disease) 12/2016
1	Angina Pectoris 12/2016
1	Diabetes Complications 11/2015
1	Diabetes Mellitus 03/2015

Drug/Important Bio-Agent (IBA)

44	AntibodiesIBA 11/2023 - 01/2001
33	Immunoglobulin M (IgM)IBA 11/2023 - 09/2006
31	Phosphorylcholine (Phosphocholine)IBA 01/2023 - 09/2006
24	oxidized low density lipoproteinIBA 01/2023 - 01/2001
10	LipidsIBA 01/2023 - 09/2002
9	Malondialdehyde (Propanedial)IBA 11/2023 - 01/2016
8	C-Reactive ProteinIBA 09/2021 - 12/2003
8	LDL Lipoproteins (beta Lipoproteins)IBA 11/2017 - 07/2003
7	AutoantibodiesIBA 01/2021 - 08/2002
6	CholesterolIBA 01/2022 - 09/2003
6	Phospholipids (Phosphatides)FDA LinkGeneric 02/2015 - 08/2002
6	Annexin A5IBA 01/2015 - 01/2005
6	lacidipineIBA 01/2014 - 09/2002
6	CytokinesIBA 10/2013 - 01/2001
5	Immunoglobulin G (IgG)IBA 11/2023 - 03/2020
5	Antiphospholipid AntibodiesIBA 01/2023 - 01/2005
4	Triglycerides (Triacylglycerol)IBA 12/2020 - 08/2002
4	ApolipoproteinsIBA 01/2015 - 01/2011
3	EpitopesIBA 01/2023 - 01/2005
3	Insulin (Novolin)FDA Link 12/2020 - 11/2006
3	HDL LipoproteinsIBA 05/2018 - 09/2003
3	PhosphatidylserinesIBA 01/2017 - 11/2013
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2015 - 09/2002
3	Cardiolipins (Cardiolipin)IBA 01/2014 - 01/2013
3	Proteins (Proteins, Gene)FDA Link 12/2013 - 11/2009
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2013 - 09/2003
3	ChromatinIBA 04/2012 - 03/2006
2	Interleukin-6 (Interleukin 6)IBA 09/2021 - 12/2003
2	HDL CholesterolIBA 12/2020 - 08/2002
2	Biomarkers (Surrogate Marker)IBA 12/2020 - 06/2012
2	Prednisolone (Predate)FDA LinkGeneric 01/2020 - 09/2007
2	AlbuminsIBA 08/2019 - 12/2016
2	Lysophosphatidylcholines (Lysophosphatidylcholine)IBA 10/2013 - 01/2001
2	LDL CholesterolIBA 01/2009 - 09/2004
1	Atorvastatin (Lipitor)FDA Link 09/2021
1	HDL-triglycerideIBA 12/2020
1	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)IBA 07/2020
1	SubtilisinIBA 07/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 07/2018
1	Transcription Factor 3IBA 01/2018
1	Interleukin-17 (Interleukin 17)IBA 01/2018
1	AntigensIBA 11/2017
1	Chaperonin 60IBA 11/2017
1	Tartrate-Resistant Acid PhosphataseIBA 01/2017
1	Interferon Type IIBA 01/2017
1	Human Serum Albumin FDA LinkGeneric 12/2016
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2016
1	MicroRNAs (MicroRNA)IBA 01/2016
1	Glucose (Dextrose)FDA LinkGeneric 11/2015
1	coenzyme Q10 (CoQ10)IBA 11/2015
1	Complement C3 (C3 Complement)IBA 03/2015
1	Complement C4 (Complement Component 4)IBA 03/2015
1	Antimalarials (Antimalarial Agents)IBA 03/2015
1	Secretory Phospholipases A2IBA 01/2015
1	Leukotriene B4IBA 08/2014
1	Therapeutic UsesIBA 08/2014

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2011